Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 16.72
+0.45 (2.77%)
Sep 30, 2026, 3:00 PM CST
Sansure Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3,719 | 3,968 | 4,590 | 4,233 | 3,213 | 2,636 |
Trading Asset Securities | 101.93 | 157.1 | 139.67 | 548.28 | 2,451 | 2,046 |
Cash & Short-Term Investments | 3,821 | 4,125 | 4,730 | 4,782 | 5,664 | 4,683 |
Cash Growth | -6.00% | -12.78% | -1.09% | -15.57% | 20.95% | 11.70% |
Accounts Receivable | 685.93 | 629.62 | 560.69 | 692.26 | 1,298 | 807.66 |
Other Receivables | 24.9 | 28.36 | 27.58 | 23.49 | 82.41 | 14.3 |
Receivables | 710.83 | 657.98 | 588.27 | 715.75 | 1,381 | 821.95 |
Inventory | 451.48 | 413.69 | 392.75 | 376.63 | 355.31 | 369.5 |
Other Current Assets | 81.09 | 77.15 | 78.7 | 75.45 | 125.83 | 92.09 |
Total Current Assets | 5,064 | 5,274 | 5,790 | 5,950 | 7,525 | 5,966 |
Property, Plant & Equipment | 1,295 | 1,335 | 1,113 | 1,043 | 785.27 | 481.03 |
Long-Term Investments | 1,624 | 1,315 | 1,096 | 974.33 | 657.43 | 513.23 |
Goodwill | 798.39 | 798.39 | 7.66 | 7.66 | - | - |
Other Intangible Assets | 523.78 | 497.4 | 334.67 | 283.28 | 79.12 | 45.55 |
Long-Term Deferred Tax Assets | 93.92 | 85.83 | 69.28 | 73.82 | 69.62 | 25 |
Long-Term Deferred Charges | 168.95 | 175.37 | 147.27 | 97.05 | 46.7 | 16.26 |
Other Long-Term Assets | 68.4 | 45.68 | 47.04 | 25.16 | 10.19 | 43.08 |
Total Assets | 9,636 | 9,527 | 8,604 | 8,454 | 9,174 | 7,090 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 191.89 | 192.33 | 225.78 | 271.14 | 586.26 | 188.82 |
Accrued Expenses | 223.34 | 260.03 | 290.03 | 363.33 | 622.39 | 231.82 |
Short-Term Debt | 108.45 | 93.51 | 9 | 9 | - | - |
Current Portion of Leases | 6.05 | 55.34 | 5.28 | 11.1 | 14.26 | 8.49 |
Current Income Taxes Payable | 6.38 | 2.59 | 0.21 | 17.66 | 145.25 | 80.16 |
Current Unearned Revenue | 34.52 | 46.88 | 64.55 | 32.81 | 53.11 | 78.64 |
Other Current Liabilities | 424.67 | 555.33 | 159.94 | 214.12 | 150.45 | 76.01 |
Total Current Liabilities | 1,085 | 1,206 | 754.8 | 919.15 | 1,572 | 663.93 |
Long-Term Debt | 1,312 | 966.3 | 396.65 | - | - | - |
Long-Term Leases | 8.85 | 12.17 | 11.92 | 18.21 | 13.6 | 6.41 |
Long-Term Unearned Revenue | 58.82 | 62.94 | 39.88 | 32.49 | 30.53 | 25.68 |
Long-Term Deferred Tax Liabilities | 97.25 | 89.16 | 54.75 | 59.45 | 19.04 | 13.01 |
Other Long-Term Liabilities | - | - | - | - | 26.09 | - |
Total Liabilities | 2,562 | 2,337 | 1,258 | 1,029 | 1,661 | 709.03 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 579.39 | 579.39 | 582.39 | 588.46 | 588.46 | 400 |
Additional Paid-In Capital | 1,563 | 1,565 | 1,702 | 1,908 | 1,914 | 2,065 |
Retained Earnings | 5,033 | 5,085 | 5,194 | 5,177 | 5,371 | 4,082 |
Treasury Stock | -206.47 | -143.23 | -274.29 | -515.33 | -392.6 | -200.01 |
Comprehensive Income & Other | 25.45 | 30.39 | 39.01 | 43.26 | 19.36 | 21.71 |
Total Common Equity | 6,995 | 7,116 | 7,243 | 7,201 | 7,501 | 6,369 |
Minority Interest | 79.77 | 73.98 | 102.56 | 223.64 | 12.16 | 12.43 |
Shareholders' Equity | 7,074 | 7,190 | 7,346 | 7,425 | 7,513 | 6,381 |
Total Liabilities & Equity | 9,636 | 9,527 | 8,604 | 8,454 | 9,174 | 7,090 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,525 | 1,127 | 422.85 | 38.31 | 27.86 | 14.9 |
Net Cash (Debt) | 2,296 | 2,998 | 4,307 | 4,743 | 5,636 | 4,668 |
Net Cash Growth | -25.99% | -30.39% | -9.20% | -15.83% | 20.74% | 12.83% |
Net Cash Per Share | 3.94 | 5.12 | 7.35 | 8.09 | 9.63 | 7.93 |
Filing Date Shares Outstanding | 568.11 | 574.86 | 573.72 | 573.52 | 578.69 | 592 |
Total Common Shares Outstanding | 570.35 | 574.86 | 573.72 | 572.21 | 578.69 | 592 |
Working Capital | 3,979 | 4,068 | 5,035 | 5,030 | 5,954 | 5,302 |
Book Value Per Share | 12.26 | 12.38 | 12.62 | 12.59 | 12.96 | 10.76 |
Tangible Book Value | 5,673 | 5,820 | 6,901 | 6,910 | 7,421 | 6,323 |
Tangible Book Value Per Share | 9.95 | 10.12 | 12.03 | 12.08 | 12.82 | 10.68 |
Buildings | 930.5 | 930.5 | 834.41 | 826.53 | 344.51 | 231.04 |
Machinery | 782.72 | 830.15 | 607.96 | 436.62 | 322.65 | 270.13 |
Construction In Progress | 107.51 | 84.83 | 3.58 | 4.59 | 267.76 | 110.45 |